Activation of GLUT proteins, in particular GLUT-1, GLUT-2, GLUT-3 and GLUT-4, has been observed in gastric cancer, ovarian cancer, squamous cell carcinoma, glioblastomas, and meningiomas, and, in these tumors, where the Warburg effect is most pronounced, efforts have been made to develop new therapeutic strategies that include stopping the influx of glucose into the tumor cell [[10], [11], [12]]. The gene discussed is SLC2A1; the disease is glioblastoma.